New option available for Alzheimer’s patients as FDA approves expanded drug use
The U.S. Food and Drug Administration has green-lit the first-ever non-antipsychotic drug treatment for agitation in Alzheimer’s disease patients. The drug, Auvelity, was originally FDA-approved